drugset

drugset / Trial / NCT04182880

Evaluate the Safety and Pharmacokinetic Profile of CPL-01 in the Management of Acute Postoperative Pain

NCT04182880 ↗

Phase 2 Completed 20 enrolled Cali Pharmaceuticals LLC

RandomizedParallel-groupTriple-blindTreatment

Summary

Evaluate the Safety and Pharmacokinetic Profile of CPL-01 in patients after mini-abdominoplasty

Timeline

Start: 2020-01-06
Primary completion: 2020-02-28
Completion: 2020-02-28

Publications

Results Pope S, Crean C, Thrasher S, Xu H, Chen PJ, Chen L, Hu D, Onel E. Comparison of Pharmacokinetics of Long-Acting Local Analgesics: CPL-01, a Novel Extended-Release Ropivacaine, Demonstrates Consistent and Predictable Exposure Compared with Liposomal Bupivacaine. Clin Drug Investig. 2025 Feb;45(2):51-58. doi: 10.1007/s40261-025-01419-w. Epub 2025 Jan 29.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Ropivacaine	Other / unclassified	200 mg	—

Indications

No indication recorded.